Unicorn Nest Logo

CR-CP Life Science Fund

Total investments

15

Average round size

60M

Portfolio companies

13

Lead investments

3

Follow on index

0.13

Exits

1

Areas of investment
BiotechnologyDrug DiscoveryHealth CareBig DataMedical DeviceMedicalLife SciencePharmaceuticalTherapeuticsBiopharma

Investments analytics

Analytics

Total investments
15
Lead investments
3
Exits
1
Follow on index
0.13
Investments by industry
  • Health Care (12)
  • Biotechnology (11)
  • Medical (6)
  • Therapeutics (4)
  • Pharmaceutical (3)
    • Show 9 more
Investments by region
  • China (6)
  • Singapore (2)
  • United States (2)
  • Belgium (2)
  • United Kingdom (1)
    • Show 1 more
Peak activity year
2020

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.
Sign Up

Quantitative data

Avg. startup age at the time of investment
10
Avg. valuation at time of investment
112M
Group Appearance index
1.00
Strategy success index
0.40

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Upgrade

Latest deals

Company name Deal date Industry Deal stage Deal size Location
EyeYon 15 Mar 2021 Health Care, Medical Device, Medical Late Stage Venture 25M Jerusalem District, Jerusalem, Israel
Novadip Biosciences 03 Nov 2022 Biotechnology, Health Care, Medical, Therapeutics Early Stage Venture 28M Walloon Brabant, Belgium, Belgium
Peak8 Partners 15 Aug 2005 Software Early Stage Venture 0 United States, Boulder, Colorado
How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.